CS-NG is equipped with an acid-degradable modality, and therefore it effectively releases combinatorially delivered cilengitide (antiangiogenic agent) and TRAIL to endothelial cells at the acidic tumour microenvironment and membrane of cancer cells respectively. This evidence concerns the gene TNFSF10 and cancer.